Top

International Journal of Clinical Oncology

Published in:

01-02-2010 | Original Article

A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain

Authors: Hidenori Takahashi, Naohito Shimoyama

Published in: International Journal of Clinical Oncology | Issue 1/2010

Abstract

Background

Neuropathic pain is regarded as one of the main causes of cancer pain refractory to standard opioid therapy in palliative care. The use of adjuvant analgesics for neuropathic cancer pain is largely empirical and the true efficacy of these adjuvant analgesics has been unknown. Gabapentin is one of the new promising anticonvulsant drugs as an adjuvant analgesic for neuropathic cancer pain.

Methods

The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study. Gabapentin was initiated in addition to the drugs currently being administered. The dose of gabapentin was titrated from 200 mg to a maximum dose of 2400 mg per day over 15 days, based on discussion with each patient. The primary endpoint variable was the numerical rating scale (NRS) of 0–10 measured using the brief pain inventory.

Results

From February 2007 to December 2007, gabapentin was administered to 24 patients that were already receiving an opioid without sufficient analgesia. Administration of gabapentin statistically reduced the worst-NRS, the least-NRS, and the average-NRS (7.3 → 5.8, 3.6 → 3.0, 5.8 → 4.5, respectively). Four patients (16.7%) were withdrawn from the study because of adverse events (headache, myoclonus, heartburn, bronchial asthma).

Conclusion

Although gabapentin might be regarded as a promising new adjuvant analgesic for neuropathic cancer pain, our results indicated that the decrease in pain score was of minimal clinical benefit. Controlled trials with other adjuvant analgesics are needed.

World Health Organization (1996) Cancer pain relief with a guide to opioid availability, 2nd edn. WHO, Geneva

Lussier D, Portenoy RK (2003) Adjuvant analgesics in pain management. Oxford Textbook of Palliative Medicine, 3rd edn. Oxford University Press, New York, pp 349–378

Zech DFJ, Grond S, Lynch J et al (1995) Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63:65–76CrossRefPubMed

Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134CrossRefPubMed

Twycross R, Wilcock A (2001) Symptom management in advanced cancer, 3rd edn. Radcliffe Medical Press, Abingdon

Wall PD, Melzack R (2005) Textbook of pain, 5th edn. Churchill Livingstone, Philadelphia

Backonja M, Beydoun A, Edwards KR et al (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831–1836CrossRefPubMed

Finnerup NB, Otto M, McQuay HJ et al (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118:289–305CrossRefPubMed

McQuay HJ, Tramer M, Nye BA et al (1996) A systematic review of antidepressants in neuropathic pain. Pain 68:217–227CrossRefPubMed

10.

Rice ASC, Maton S (2001) Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain 94:215–224CrossRefPubMed

11.

Rosenstock J, Tuchman M, LaMoreaux L et al (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110:628–638CrossRefPubMed

12.

Rowbotham M, Harden N, Stacey B et al (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280:1837–1842CrossRefPubMed

13.

Serpell MG (2002) Gabapentin in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Pain 99:557–566CrossRefPubMed

14.

Sindrup SH, Jensen TS (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389–400CrossRefPubMed

15.

Gilron I, Bailey JM, Tu D et al (2005) Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352:1324–1334CrossRefPubMed

16.

Bruera E, Ripamonti C, Brenneis C et al (1992) A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic pain. J Pain Symptom Manage 7:138–140CrossRefPubMed

17.

Mercadante S, Arcuri E, Tirelli W et al (2000) Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized controlled, double-blind, crossover, double dose study. J Pain Symptom Manage 20:246–262CrossRefPubMed

18.

Mercadante S (2002) Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori 88:239–242PubMed

19.

Sinnott C (2002) Problems recruiting cancer patients to comparative clinical trial of drug treatments for neuropathic pain in palliative care. J Pain Symptom Manage 23:270–272CrossRefPubMed

20.

Luo ZD, Calcutt NA, Higuera ES et al (2002) Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 303:1199–1205CrossRefPubMed

21.

Partridge B, Chaplan SR, Sakamoto E et al (1998) Characterization of the effects of gabapentin and 3-isobutyl-gamma-aminobutyric acid on substance P-induced thermal hyperalgesia. Anesthesiology 88:196–205CrossRefPubMed

22.

Shimoyama M, Shimoyama N, Inturrisi CE et al (1997) Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test. Pain 72:375–382CrossRefPubMed

23.

Wiffen PJ, McQuay HJ, Edwards JE et al (2005) Gabapentin for acute and chronic pain. Cochrane database of systematic reviews issue 3. Art. No.: CD005452. doi:10.1002/14651858.CD005452

24.

Bennett MI, Simpson KH (2004) Gabapentin in the treatment of neuropathic pain. Palliat Med 18:5–11CrossRefPubMed

25.

Field MJ, Oles RJ, Lewis AS et al (1997) Gabapentin (Neurontin) and S-(+)-3-isobutyl-gaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 121:1513–1522CrossRefPubMed

26.

Gee NS, Brown JP, Dissanayake VU et al (1996) The novel anticonvulsant drug gabapentin binds to the α₂δ subunit of a calcium channel. J Biol Chem 271:5768–5776CrossRefPubMed

27.

Shimoyama M, Shimoyama N, Hori Y (2000) Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 85:405–414CrossRefPubMed

28.

Matthews EA, Dickenson AH (2002) A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology 96:633–640CrossRefPubMed

29.

Caraceni A, Zecca E, Martini C et al (1999) Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 17:441–445CrossRefPubMed

30.

Chandler A, Williams JE (2000) Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital. J Pain Symptom Manage 20:82–86CrossRefPubMed

31.

Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol 22:2909–2917CrossRefPubMed

32.

Ross JR, Goller K, Hardy J et al (2005) Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J Palliat Med 8:1118–1126CrossRefPubMed

33.

Keskinbora K, Pekel AF, Aydinli I (2007) Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manage 34:183–189CrossRefPubMed

34.

Takahashi H, Toya M, Shuto M et al (2007) The development of cancer pain management and palliative care over the last 5 years in Japan. Eur J Pain Suppl 1:14–18CrossRef

35.

Uki J, Mendoza T, Cleeland CS et al (1998) A brief cancer pain assessment tool in Japanese: the utility of the Japanese brief pain inventory-BPI-J. J Pain Symptom Manage 16:364–373CrossRefPubMed

36.

Melzack R (1987) The short-form McGill pain Questionnaire. Pain 30:191–197CrossRefPubMed

37.

Farrar JT, Young JP, LaMoreaux L et al (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158CrossRefPubMed

38.

Farrar JT, Portenoy RK, Berlin JA et al (2000) Defining the clinically important difference in pain outcome measures. Pain 88:287–294CrossRefPubMed

Title: A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain
Authors: Hidenori Takahashi
Naohito Shimoyama
Publication date: 01-02-2010
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-009-0009-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Fat replacement of the malignant pancreatic tissue after neoadjuvant therapy

Neck dissection revisited

Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer

Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes

Elevation of serum carcinoembryonic antigen level in a patient with hypothyroidism after radiation therapy for cervical esophageal cancer

Prediction of high-grade squamous intraepithelial lesions using the modified Reid index

Keynote webinar | Spotlight on antibody–drug conjugates in cancer